Overview

Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved with a b-blocker, atenolol.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Atenolol
Eplerenone
Spironolactone